UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Sharing Lessons Learned to Build Effective Hepatitis Elimination Programs

The Journal of infectious diseases, 2023-09, Vol.228 (Supplement_3), p.S145-S147

2023

Volltextzugriff (PDF)

Hepatitis C virus leaves an epigenetic signature post cure of infection by direct-acting antivirals

PLoS genetics, 2019-06, Vol.15 (6), p.e1008181

2019

Volltextzugriff (PDF)

Hepatitis C treatment from “response‐guided” to “resource‐guided” therapy in the transition era from interferon‐containing to interferon‐free regimens

Journal of gastroenterology and hepatology, 2017-08, Vol.32 (8), p.1436-1442

Yu, Ming‐Lung

2017

Volltextzugriff (PDF)

Cure With Interferon‐Free Direct‐Acting Antiviral Is Associated With Increased Survival in Patients With Hepatitis C Virus‐Related Hepatocellular Carcinoma From Both East and West

Hepatology (Baltimore, Md.), 2020-06, Vol.71 (6), p.1910-1922

2020

Volltextzugriff (PDF)

A Long Noncoding RNA Regulates Hepatitis C Virus Infection Through Interferon Alpha–Inducible Protein 6

Hepatology (Baltimore, Md.), 2019-03, Vol.69 (3), p.1004-1019

2019

Volltextzugriff (PDF)

Treatment of chronic hepatitis C in Asia: When East meets West

Journal of gastroenterology and hepatology, 2009-03, Vol.24 (3), p.336-345

2009

Volltextzugriff (PDF)

Association Between Fatty Liver and Cirrhosis, Hepatocellular Carcinoma, and Hepatitis B Surface Antigen Seroclearance in Chronic Hepatitis B

The Journal of infectious diseases, 2021-07, Vol.224 (2), p.294-302

2021

Volltextzugriff (PDF)

Strategies for Removal of Barriers to Hepatitis C Elimination in Sub-Saharan Africa

The Journal of infectious diseases, 2023-09, Vol.228 (Supplement_3), p.S221-S225

2023

Volltextzugriff (PDF)

HCV Microelimination for High-risk Special Populations

The Journal of infectious diseases, 2023-09, Vol.228 (Supplement_3), p.S168-S179

2023

Volltextzugriff (PDF)

Poor Diagnostic Efficacy of Noninvasive Tests for Advanced Fibrosis in Obese or Younger Than 60 Diabetic NAFLD patients

Clinical gastroenterology and hepatology, 2023-04, Vol.21 (4), p.1013-1022.e6

2023

Volltextzugriff (PDF)

Hepatitis C virus micro‐elimination in people who inject drugs: Challenges and chance in Taiwan and worldwide

The Kaohsiung journal of medical sciences, 2024-02, Vol.40 (2), p.112-118

2024

Volltextzugriff (PDF)

Systematic review with meta‐analysis: extrahepatic manifestations in chronic hepatitis C virus‐infected patients in East Asia

Alimentary pharmacology & therapeutics, 2019-03, Vol.49 (6), p.644-653

2019

Volltextzugriff (PDF)

Poor adherence to hepatocellular carcinoma surveillance: A systematic review and meta‐analysis of a complex issue

Liver international, 2018-03, Vol.38 (3), p.503-514

2018

Volltextzugriff (PDF)

Short duration of direct-acting antivirals for acute HCV infection

The Lancet infectious diseases, 2017-05, Vol.17 (5), p.481-482

Yu, Ming-Lung

2017

Volltextzugriff (PDF)

Hepatitis C virus infection increases risk of developing end-stage renal disease using competing risk analysis

PloS one, 2014-06, Vol.9 (6), p.e100790-e100790

2014

Volltextzugriff (PDF)

Body weight increase and metabolic derangements after tenofovir disoproxil fumarate switch to tenofovir alafenamide in patients with chronic hepatitis B

Alimentary pharmacology & therapeutics, 2024-01, Vol.59 (2), p.230-238

2024

Volltextzugriff (PDF)

Prevalence, proportions of elevated liver enzyme levels, and long‐term cardiometabolic mortality of patients with metabolic dysfunction‐associated steatotic liver disease

Journal of gastroenterology and hepatology, 2024-09, Vol.39 (9), p.1939-1949

2024

Volltextzugriff (PDF)

APASL HCV guidelines of virus-eradicated patients by DAA on how to monitor HCC occurrence and HBV reactivation

Hepatology international, 2019-11, Vol.13 (6), p.649-661

2019

Volltextzugriff (PDF)

Comorbidities, concomitant medications and potential drug‐drug interactions with interferon‐free direct‐acting antiviral agents in hepatitis C patients in Taiwan

Alimentary pharmacology & therapeutics, 2018-12, Vol.48 (11-12), p.1290-1300

2018

Volltextzugriff (PDF)

Path from the discovery to the elimination of hepatitis C virus: Honoring the winners of the Nobel Prize in Physiology or Medicine 2020

The Kaohsiung journal of medical sciences, 2021-01, Vol.37 (1), p.7-11

2021

Volltextzugriff (PDF)

Cardiovascular risk of tenofovir disoproxil fumarate or tenofovir alafenamide in patients with chronic hepatitis B: More questions than an answer

Clinical and Molecular Hepatology, 2024, 30(2), , pp.144-146

2024

Volltextzugriff (PDF)

Increased spine bone density in patients with chronic hepatitis B switched to tenofovir alafenamide: A prospective, multinational study

Alimentary pharmacology & therapeutics, 2024-01, Vol.59 (2), p.239-248

2024

Volltextzugriff (PDF)

Liquid Biopsy for the Diagnosis of Viral Hepatitis, Fatty Liver Steatosis, and Alcoholic Liver Diseases

International journal of molecular sciences, 2020-05, Vol.21 (10), p.3732

2020

Volltextzugriff (PDF)

Are immune-checkpoint inhibitors immunosuppressive to hepatitis B virus?

Hepatology international, 2022-04, Vol.16 (2), p.482-483

2022

Volltextzugriff (PDF)

Role of interleukin‐28B polymorphisms in the treatment of hepatitis C virus genotype 2 infection in Asian patients

Hepatology (Baltimore, Md.), 2011-01, Vol.53 (1), p.7-13

2011

Volltextzugriff (PDF)

1 – 25 von 913

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(859)
Mit Volltextzugriff
(857)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(685)
Life Sciences & Biomedicine
(515)
Humans
(484)
Male
(362)
Female
(348)
Middle Aged
(301)
Adult
(250)
Gastroenterology & Hepatology
(218)
Hepatitis C
(200)
Aged
(188)
Hepatitis
(188)
Patients
(162)
Hepatitis C Virus
(159)
Antiviral Agents - Therapeutic Use
(152)
Hepatitis C, Chronic - Drug Therapy
(146)
Science & Technology - Other Topics
(139)
Liver
(133)
Multidisciplinary Sciences
(129)
Infections
(128)
Risk Factors
(127)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(3)
... seit 90 Tagen
(14)

Menü

Weitere Dienste

Einstellungen

Sharing Lessons Learned to Build Effective Hepatitis Elimination Programs

Hepatitis C virus leaves an epigenetic signature post cure of infection by direct-acting antivirals

Hepatitis C treatment from “response‐guided” to “resource‐guided” therapy in the transition era from interferon‐containing to interferon‐free regimens

Cure With Interferon‐Free Direct‐Acting Antiviral Is Associated With Increased Survival in Patients With Hepatitis C Virus‐Related Hepatocellular Carcinoma From Both East and West

A Long Noncoding RNA Regulates Hepatitis C Virus Infection Through Interferon Alpha–Inducible Protein 6

Treatment of chronic hepatitis C in Asia: When East meets West

Association Between Fatty Liver and Cirrhosis, Hepatocellular Carcinoma, and Hepatitis B Surface Antigen Seroclearance in Chronic Hepatitis B

Strategies for Removal of Barriers to Hepatitis C Elimination in Sub-Saharan Africa

HCV Microelimination for High-risk Special Populations

Poor Diagnostic Efficacy of Noninvasive Tests for Advanced Fibrosis in Obese or Younger Than 60 Diabetic NAFLD patients

Hepatitis C virus micro‐elimination in people who inject drugs: Challenges and chance in Taiwan and worldwide

Systematic review with meta‐analysis: extrahepatic manifestations in chronic hepatitis C virus‐infected patients in East Asia

Poor adherence to hepatocellular carcinoma surveillance: A systematic review and meta‐analysis of a complex issue

Short duration of direct-acting antivirals for acute HCV infection

Hepatitis C virus infection increases risk of developing end-stage renal disease using competing risk analysis

Body weight increase and metabolic derangements after tenofovir disoproxil fumarate switch to tenofovir alafenamide in patients with chronic hepatitis B

Prevalence, proportions of elevated liver enzyme levels, and long‐term cardiometabolic mortality of patients with metabolic dysfunction‐associated steatotic liver disease

APASL HCV guidelines of virus-eradicated patients by DAA on how to monitor HCC occurrence and HBV reactivation

Comorbidities, concomitant medications and potential drug‐drug interactions with interferon‐free direct‐acting antiviral agents in hepatitis C patients in Taiwan

Path from the discovery to the elimination of hepatitis C virus: Honoring the winners of the Nobel Prize in Physiology or Medicine 2020

Cardiovascular risk of tenofovir disoproxil fumarate or tenofovir alafenamide in patients with chronic hepatitis B: More questions than an answer

Increased spine bone density in patients with chronic hepatitis B switched to tenofovir alafenamide: A prospective, multinational study

Liquid Biopsy for the Diagnosis of Viral Hepatitis, Fatty Liver Steatosis, and Alcoholic Liver Diseases

Are immune-checkpoint inhibitors immunosuppressive to hepatitis B virus?

Role of interleukin‐28B polymorphisms in the treatment of hepatitis C virus genotype 2 infection in Asian patients

Suchergebnisse filtern